medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2021, Number 4

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2021; 19 (4)

Androgenetic Alopecia: Review of Treatments and New Therapeutic Options

Language: Spanish
References: 38
Page: 369-375
PDF size: 151.30 Kb.


ABSTRACT

Androgenetic alopecia (AGA) is characterized by a progressive miniaturization without scars of the hair follicle with a patterned distribution in predisposed men and women. It is one of the most common causes of hair consultation. The etiopathogenesis is based on a progressive miniaturization of the hair follicle that leads to the hairy transformation of the terminal hair and is mediated genetically and by androgenic stimulation. There are specific trichoscopic data to facilitate its diagnosis. The goal of treatment is to avoid the miniaturization process and, if possible, reverse it. It must be individualized for each patient and depends on several factors, including efficacy, feasibility, risks and also costs since it is for life. Existing and some emerging therapies such as oral minoxidil, dutasteride, platelet-rich-plasma (PRP), cortexolone 17 α-propionate, spironolactone, cyproterone acetate, flutamide, bicalutamide, activators of the Wnt/β-catenin pathway and microneedling are analyzed in order to offer personalized treatments that improve the quality of life of patients


REFERENCES

  1. Kelly Y, Blanco A y Tosti A, Androgenetic alopecia: an update of treatment options, Drugs 2016; 76:1349–64. doi:10.1007/s40265-016-0629-5.

  2. Pierard-Franchimont C y Pierard G, Teloptosis, a turning point in hair shedding biorhythms, Dermatology 2001; 203:115-7. doi: 10.1159/000051723.

  3. Katzer T, Leite A, Beck R y Silva C, Physiopathology and current treatments of androgenetic alopecia: going beyond androgens and antiandrogens Dermatologic Therapy 2019; 32: e13059. doi: 10.1111/dth.13059.

  4. Lolli F et al., Androgenetic alopecia: a review, Endocrine 2017; 57:9-17. doi: 10.1007/s12020-017-1280-y.

  5. Premanand A y Reena B, Androgen modulation of Wnt/β-catenin signaling in androgenetic alopecia, Arch Dermatol Res 2018; 310:391-9. doi: 10.1007/s00403-018-1826-8.

  6. Goren A y Naccarato T, Minoxidil in the treatment of androgenetic alopecia, Dermatologic Therapy 2018; 31:e12686. doi:10.1111/dth.12686.

  7. Roberts J, Desai N, McCoy J y Goren A, Sulfotransferase activity in plucked hair follicles predicts response to topical minoxidil in the treatment of female androgenetic alopecia, Dermatologic Therapy 2014; 27:252-4. doi: 10.1111/dth.12130.

  8. McCoy J, Goren A, Kovacevic M y Shapiro J, Minoxidil dose response study in female pattern hair loss patients determined to be nonresponders to 5% topical minoxidil, Journal of Biological Regulators and Homeostatic Agents 2016; 30:1153-5.

  9. Jiménez J et al., Effectiveness and safety of low-dose oral minoxidil in male androgenetic alopecia, Journal of the American Academy of Dermatology 2019; 81:648-9. doi: 10.1016/j.jaad.2019.04.054.

  10. Mella J, Perret M, Manzotti M, Catalano H y Guyatt G, Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review, Arch Dermatol 2010; 146:1141-50. doi: 10.1001/archdermatol.2010.256.

  11. Rossi A et al., Finasteride, 1 mg daily administration on male androgenetic alopecia in different age groups: 10-year follow-up, Dermatol Therapy 2011; 24:455-61. doi: 10.1111/j.1529-8019.2011.01441.x.

  12. Mysore V y Shashikumar B, Guidelines on the use of finasteride in androgenetic alopecia, Indian J Dermatol Venereol Leprol 2016; 82:128-134. doi: 10.4103/0378-6323.177432.

  13. Caserini M et al., Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men with androgenetic alopecia, Int J Clin Pharmacol Ther 2016; 54:19-27. doi: 10.5414/CP202467.

  14. Lee, S et al., Adverse sexual effects of treatment with finasteride or dutasteride for male androgenetic alopecia: a systematic review and metaanalysis, Acta Derm Venereol 2019; 99:12-17. doi: 10.2340/00015555-3035.

  15. Gur S, Kadowitz P y Hellstrom W, Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation, Expert Opin Drug Saf 2013; 12:81-90. doi: 10.1517/14740338.2013.742885.

  16. Gray S y Semla T, Post-finasteride syndrome, bmj 2019; 366:l5047. doi: 10.1136/bmj.l5047.

  17. Clark R et al., Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor, J Clin Endocrinol Metab 2004; 89:2179-84. doi: 10.1210/ jc.2003-030330.

  18. Jung J et al., Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride, Int J Dermatol 2014; 53:1351-7. doi: 10.1111/ijd.12060.

  19. Shanshanwal S y Dhurat R, Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: a randomized controlled open-label, evaluatorblinded study, Indian J Dermatol Venereol Leprol 2017; 83:47-54. doi: 10.4103/0378-6323.188652.

  20. Saceda D et al., Mesotherapy with dutasteride in the treatment of androgenetic alopecia, Int J Trichology 2017; 9:143-5. doi:10.4103/ijt.ijt_73_16.

  21. Vañó S y Camacho F, New treatments for hair loss, Actas Dermosifiliogr 2017; 108:221-228. doi: 10.1016/j.ad.2016.11.010.

  22. Giordano S, Romeo M y Lankinen P, Plated-rich plasma for androgenetic alopecia: does it work? Evidence from meta-analysis, J Cosmet Dermatol 2017; 16:374-381. doi: 10.1111/jocd.12331.

  23. Mao G, Zhang G y Fan W, Platelet-rich plasma for treating androgenic alopecia: a systematic review, Aesthetic Plastic Surgery 2019. doi:10.1007/ s00266-019-01391-9.

  24. Sharma V, Bhari N, Patra V y Singh A, Platelet-rich plasma therapy for androgenetic alopecia, Indian J Dermatol 2019; 64:417-9. doi: 10.4103/ ijd.ijd_363_17.

  25. Andrasfay A, A phase 2 study to evaluate the safety and efficacy of cb-03-01 solution, a comparator solution and vehicle solution in males with androgenetic alopecia, ClinicalTrials 2016; nct02279823.

  26. Rathnayake D y Sinclair R, Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss, Dermatol Clin 2010; 28:611-8. doi: 10.1016/j.det.2010.03.011.

  27. Sinclair R, Wewerinke M y Jolley D, Treatment of female pattern hair loss with oral antiandrogens, Br J Dermatol 2005; 152:466-73. doi: 10.1111/j.1365-2133.2005.06218.x.

  28. Vexiau P et al., Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial, Br J Dermatol 2002; 146:992-9. doi: 10.1046/j.1365-2133.2002.04798.x.

  29. Acetato de ciproterona a dosis altas (Androcur®) y riesgo de meningioma: nuevas restricciones de uso, Agencia Española de Medicamentos y Productos Sanitarios, febrero de 2020.

  30. Ezeh U, Huang A, Landay M y Azziz R, Long-term response of hirsutism and other hyperandrogenic symptoms to combination therapy in polycystic ovary syndrome, J Womens Health (Larchmt) 2018; 27:892.

  31. Paradisi R et al., Prospective cohort study on the effects and tolerability of flutamide in patients with female pattern hair loss, Ann Pharmacother 2011; 45;469-75. doi: 10.1345/aph.1P600.

  32. Ismail F et al., Safety of oral bicalutamide in female pattern hair loss: a retrospective review of 316 patients, J Am Acad Dermatol 2020; 83:1478-9. doi: 10.1016/j.jaad.2020.03.034.

  33. Tosti A et al., Topical application of the Wnt/β-catenin activator methyl vanillate increases hair count and hair mass index in women with androgenetic alopecia, J Cosmet Dermatol 2016; 15:469-74. doi: 10.1111/jocd.12225.

  34. Lee S et al., Valproic acid induces hair regeneration in murine model and activates alkaline phosphatase activity in human dermal papilla cells, plos One 2012; 7:e34152. doi:10.1371/journal.pone.0034152.

  35. Yazici Y et al., Safety and efficacy of a topical treatment (sm04554) for androgenetic alopecia (aga): results from a phase 1 trial, Journal of the American Academy of Dermatology 2016; 74:ab138. doi:10.1016/j. jaad.2016.02.544.

  36. Won CH et al., Hair growth-promoting effects of adiponectin in vitro, J Invest Dermatol 2012; 132:2849-51. doi: 10.1038/jid.2012.217.

  37. Dhurat R y Mathapati S, Response to microneedling treatment in men with androgenetic alopecia who failed to respond to conventional therapy, Indian J Dermatol 2015; 60:260-3. doi: 10.4103/0019-5154.156361.

  38. Leavitt M, Charles G, Heyman E y Michaels D, HairMax LaserComb laser phototherapy device in the treatment of male androgenetic alopecia: a randomized, double-blind, sham device-controlled, multicentre trial, Clin Drug Investig 2009; 29:283-92. doi: 10.2165/00044011-200929050-00001




2020     |     www.medigraphic.com